The CD46 low cells, roughly equated to the LCE-multiple myeloma subpopulations, showed intrinsic resistance to the IMiDs, but remained sensitive to proteosome inhibitors and daratumumab (Fig. 3D). Here, CD46 is linked to plasma cell myeloma.